389 studies found for:    nicotinamide
Show Display Options
Rank Status Study
1 Unknown  Nicotinamide Versus Sevelamer Hydrochloride on Phosphatemia Control on Chronic Hemodialysed Patients
Conditions: Chronic Renal Failure;   Hemodialysis
Interventions: Drug: nicotinamide;   Drug: sevelamer;   Drug: cinacalcet
2 Recruiting Niacin on Immune Activation : a Proof-of-concept Study
Condition: HIV
Intervention: Drug: Niacin
3 Completed Biosynthesis of PGD2 in Vivo
Condition: Healthy Volunteer
Interventions: Dietary Supplement: 5 days of placebo followed by 600mg niacin;   Dietary Supplement: aspirin first;   Drug: 81 mg Aspirin;   Dietary Supplement: Niaspan;   Drug: Celebrex and niacin
4 Recruiting Nicotinamide Safety Study
Conditions: Pregnancy Induced Hypertension;   Superimposed Preeclampsia;   Hypertension
Intervention: Drug: Nicotinamide
5 Completed Short-term Effect of Extended-release Niacin on Endothelial Function.
Condition: Hypoalphalipoproteinemia
Intervention: Drug: Niacin
6 Unknown  Evaluation of the Effect of NICOtinic Acid (Niacin) on Elevated Lipoprotein(a) Levels (NICOLa Study)
Condition: Elevated Lipoprotein(a) Levels
Interventions: Drug: Nicotinic acid (niacin);   Drug: Placebo
7 Completed Effect of Niacin in the Lipoprotein (a) Concentration
Condition: Hypercholesterolemia
Intervention: Drug: Niacin/Laropiprant
8 Completed
Has Results
A Study to Evaluate the Effects of ER Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites (0524A-079)(COMPLETED)
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Comparator: ER niacin (+) laropiprant;   Drug: Comparator: ER niacin;   Drug: Comparator: laropiprant;   Drug: Comparator: placebo
9 Completed
Has Results
A Study to Evaluate the Effects of Extended Release (ER) Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With High Cholesterol (0524A-075)(COMPLETED)
Condition: Hypercholesterolemia
Interventions: Drug: Comparator: niacin + laropiprant;   Drug: Comparator: niacin;   Drug: Comparator: laropiprant;   Drug: Comparator: placebo
10 Completed SLIM: Combined Effects of Slo-Niacin and Atorvastatin on Lipoproteins and Inflammatory Markers in Hyperlipidemia
Condition: Dyslipidemia
Intervention: Drug: Slo-Niacin, atorvastatin
11 Completed Niacin/Laropiprant and Endothelial Function
Condition: Coronary Heart Disease
Interventions: Drug: Niacin/laropiprant;   Drug: Placebo
12 Completed Effect of Niacin on Transport of HDL and Relationship to Atherogenic Lipoproteins and Lipolysis
Condition: Healthy Volunteers
Interventions: Drug: Niacin;   Other: Placebo
13 Recruiting Uncontrolled, Open Label, Pilot and Feasibility Study of Niacinamide in Polycystic Kidney Disease
Condition: Polycystic Kidney Disease
Intervention: Dietary Supplement: Niacinamide
14 Active, not recruiting Olive Oil on Nampt and Its Relation With Postprandial Inflammation and Atherosclerosis in the Setting of Metabolic Syndrome.
Condition: Metabolic Syndrome
Interventions: Dietary Supplement: Niacin;   Dietary Supplement: Saturated meal;   Dietary Supplement: Monounsaturated meal;   Dietary Supplement: Polyunsaturated meal
15 Completed Nicotinamide in the Treatment of Psoriasis
Condition: Psoriasis
Interventions: Drug: Calcipotriol plus Nicotinamide;   Drug: Calcipotriol
16 Active, not recruiting Safety Study of Nicotinamide to Treat Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: Nicotinamide;   Drug: Enduramide placebo
17 Recruiting Effect of Nicotinamide in Friedreich's Ataxia
Condition: Neurodegenerative Disorders
Intervention: Drug: nicotinamide
18 Terminated
Has Results
A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158)
Conditions: Hypercholesterolemia, Familial;   Heterozygous Familial Hypercholesterolemia
Intervention: Drug: MK-0524A
19 Completed
Has Results
To Evaluate Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) in Patients With Type IIa or Type IIb Hyperlipidemia (0653A-091)(COMPLETED)
Condition: Hypercholesterolemia
Interventions: Drug: Comparator: ezetimibe/simvastatin + niacin (ER);   Drug: Comparator: Placebo to ezetimibe/simvastatin;   Drug: Comparator: niacin (ER) tablet;   Drug: Comparator: ezetimibe (+) simvastatin;   Drug: Comparator: Placebo to Niacin (ER);   Drug: Comparator: ezetimibe/simvastatin and niacin (ER);   Drug: Comparator: ezetimibe and simvastatin;   Drug: Comparator: Placebo to niacin (ER)
20 Terminated ER Niacin/Laropiprant Impact on Cardiovascular Markers and Atheroprogression in HIV-infected Individuals on cART
Conditions: HIV;   Atherosclerosis
Interventions: Drug: niacin/laropiprant;   Drug: Placebo

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years